Ethylene oxide (ETO) sterilization is the method of choice for heat- and moisture-sensitive medical devices, but residual EO and its reaction by-products can pose significant toxicological risks to patients. ETO residual testing verifies that sterilized products meet the allowable exposure limits defined in ISO 10993-7 and equivalent national standards before they are released to market. This article explains the applicable standards, sample types, analytical methods, acceptance criteria, and frequently asked questions related to medical device ETO residual testing.
Technical Overview
Ethylene oxide (EO, also written ETO or EtO) sterilization is a low-temperature gaseous process, typically operated between 37 °C and 63 °C, that is widely used for medical devices that cannot withstand steam or dry-heat sterilization. The gas penetrates breathable sterile packaging and is compatible with most thermoplastic polymers, making it the preferred sterilization method for a large share of single-use devices. Process development, validation, and routine control of EO sterilization are governed by ISO 11135 and its nationally adopted equivalents.
Because ethylene oxide is a highly reactive alkylating agent, measurable residues remain adsorbed in device materials, adhesives, and packaging after sterilization. During and after the cycle, EO also reacts with water and chloride ions to form secondary residues, primarily ethylene glycol (EG) and 2-chloroethanol, commonly known as ethylene chlorohydrin (ECH). Residual EO is a known mucosal irritant, sensitizer, and genotoxic agent, and it is internationally classified as a human carcinogen, so patient exposure must be strictly limited.
The international framework for evaluating these residues is ISO 10993-7 (biological evaluation of medical devices, ethylene oxide sterilization residuals), which is adopted in Europe as EN ISO 10993-7 and in China as GB/T 16886.7. For disposable infusion, transfusion, and injection equipment, GB/T 14233.1 specifies the corresponding chemical test methods and product-level residual criteria. Testing is normally performed by accredited third-party laboratories operating under ISO/IEC 17025 quality management systems, and the results support design validation, sterilization and aeration validation, regulatory submission, and routine batch release.
Testing Samples
Surface-Contacting Devices
Devices that contact intact skin or mucosal membranes for limited or prolonged periods, such as wound dressings, absorbent pads, adhesive tapes, surgical drapes and gowns, and barrier products, absorb EO into fibrous and polymeric layers and require residual assessment appropriate to their contact duration.
External Communicating Devices
Devices that communicate with the blood path or internal tissues, including disposable syringes, infusion and transfusion sets, intravenous cannulae, urinary and vascular catheters, endotracheal tubes, breathing circuits, hemodialyzers, and blood oxygenators, represent the highest-risk category because residuals can be delivered directly to the patient during clinical use.
Implantable Devices
Long-term and permanent implants sterilized with EO, such as absorbable sutures, hernia meshes, intrauterine devices, and polymer-based fixation components, are evaluated against the strictest residual limits because patient exposure extends over weeks, months, or the service life of the implant.
Materials, Components, and Packaging
Polymer resins, adhesives, coated components, and sterile barrier packaging materials are tested during design and development to characterize EO uptake and dissipation behavior, to support material selection, and to define appropriate aeration (degassing) conditions for the finished product.
Testing Items
Depending on the product standard, intended use, and risk assessment, an ETO residual evaluation typically includes the following items:
- Ethylene oxide (EO) residual content, reported as mg per device or μg per gram of product
- Ethylene chlorohydrin (ECH, 2-chloroethanol) residual content
- Ethylene glycol (EG) residual content, where required by legacy specifications or customer agreements
- Simulated-use extraction results, expressing the dose actually delivered to the patient during clinical use
- Exhaustive extraction results, expressing the total residual burden remaining in the product
- Aeration or dissipation kinetic studies showing how residuals decline as a function of post-sterilization time and storage conditions
Testing Methods
Sample Preparation and Extraction
ISO 10993-7 defines two complementary extraction approaches. Simulated-use extraction places the device in water or another clinically relevant fluid at approximately 37 °C for a duration that reflects actual product use, and it is the preferred method for devices that contact aqueous fluids. Exhaustive extraction repeatedly extracts the same sample until the residue recovered in the final extraction is negligible compared with the cumulative total, and it is used to determine the total residual load, particularly for devices where clinical use does not fully exhaust the available residue. Samples must be sealed in gas-tight containers immediately after collection and transported promptly, because EO dissipates continuously after sterilization.
Instrumental Analysis
The reference analytical technique is gas chromatography (GC). EO is most commonly quantified by headspace gas chromatography with flame ionization detection (HS-GC-FID), in which the extract is equilibrated in a sealed headspace vial at an elevated temperature and the evolved gas phase is injected into the column. ECH is determined by GC using FID or, for higher sensitivity, electron capture detection (ECD), with GC-MS available for confirmation when required. Quantification is performed against external calibration standards prepared from certified reference materials, covering the working range expected for the product.
Method Validation and Quality Control
Accredited third-party laboratories validate the method for each matrix by demonstrating linearity of the calibration curve, method precision, spike recovery (accuracy), limits of detection and quantification, and chromatographic specificity against co-extracted substances. Batch quality control includes calibration verification, duplicate or triplicate sample analysis, and control charts to ensure the reliability of every reported result.
Data Evaluation and Acceptance Criteria
Measured concentrations are converted into the total residual dose delivered to the patient and compared with the tolerable limits of ISO 10993-7, which are stratified by the duration of device-body contact:
- Limited contact (up to 24 hours): EO not more than 4 mg; ECH not more than 38 mg
- Prolonged contact (24 hours to 30 days): EO not more than 2 mg; ECH not more than 19 mg
- Permanent contact (more than 30 days): EO not more than 0.1 mg; ECH not more than 2 mg
Where multiple devices are used on the same patient in one day, the doses must be summed. In addition, product-specific standards may impose concentration-based criteria; for example, disposable infusion and transfusion sets are commonly required to contain no more than 10 μg of EO per gram of product in accordance with the relevant GB/T 14233.1-based requirements.
Applications
ETO residual testing supports the entire life cycle of ethylene-oxide-sterilized medical devices:
- Regulatory registration dossiers and technical documentation for market access in China, the European Union, North America, and other jurisdictions
- Initial validation and periodic requalification of EO sterilization processes in accordance with ISO 11135
- Development and optimization of aeration (degassing) cycles, including loading configuration and hold-time definition
- Routine batch release testing as part of the manufacturer's release strategy
- Shelf-life and stability studies demonstrating that residuals remain compliant throughout the labeled storage period
- Material, adhesive, and sterile-packaging selection during design transfer
- Investigation and corrective action for out-of-specification residual findings
FAQ
Which devices require ETO residual testing?
Any medical device that is sterilized with ethylene oxide and contacts a patient, whether through intact skin, mucosal membranes, the blood path, or implantation, should be evaluated for EO and ECH residuals as part of its biological safety assessment under ISO 10993-7.
When should samples be taken after sterilization?
For routine release, samples are taken after the defined aeration period at the point of product release, which represents the worst case for the patient. For process and aeration validation, samples are collected at several post-sterilization intervals to build a dissipation profile. In all cases, samples must be sealed immediately in gas-tight containers and tested as soon as possible, since EO continues to dissipate over time.
What is the difference between simulated-use and exhaustive extraction?
Simulated-use extraction estimates the residual dose a patient actually receives during normal clinical use of the device, while exhaustive extraction measures the total residual quantity remaining in the product. The appropriate method depends on the device's use scenario, its materials, and the contact duration category applied in ISO 10993-7.
Why is ethylene chlorohydrin tested together with EO?
ECH is formed when EO reacts with chloride-containing substances during or after sterilization. It is toxic in its own right, so a product with acceptable EO levels could still expose the patient to excessive ECH; ISO 10993-7 therefore sets independent limits for both compounds.
Can products be re-aerated if residuals exceed the limits?
Yes, within a documented quality system, finished goods may undergo additional aeration, after which retesting must demonstrate compliance. Any re-aeration step should be justified, recorded, and verified with representative residual data, and the root cause of the exceedance should be investigated to prevent recurrence.
How are the results reported?
Results are typically reported as residual mass per device and as concentration in μg/g, together with the calculated patient-delivered dose, the extraction method used, the analytical conditions, and a clear conclusion of conformity against the applicable limits of ISO 10993-7, EN ISO 10993-7, or the relevant GB/T product standards.